News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
News Bavarian and BMS press on with Opdivo and cancer vaccine com... BMS hopes combinations will maintain Opdivo lead after setback
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Imbruvica, Opdivo and Praluent gain approvals for Scotland’s... Sanofi steals a march on rivals Amgen
News BMS' Opdivo stumbles in lung cancer, but could still maintai... Analysts expect Opdivo to recover via combination trials
Cancer Ambition trips BMS as Opdivo fails in frontline lung cancer Major setback for BMS, giving Merck's Keytruda the advantage
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
